Global Biotech Market Analysis and Forecasts, 2008-2023

Questions: Discounts, Updates etc.

Pages: 150

Price (Single): £1499

Price (Departmental): £2999

Price (Company): £4999

Publication Date: 2008-08-16

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970’s. The leading biotechnology company, Amgen, is now amongst the largest pharmaceutical companies in the world, with other biotechnology companies catching up. The global biotech drug market was worth over $75bn in 2007, with double-figure growth noticeably higher that that of the overall pharmaceutical market.

Over the period from 2008 to 2023, visiongain expects the healthcare biotechnological market to continue its strong growth, with exciting new developments both technologically and commercially. Increased R&D efforts, shorter approval times and innovative new treatments are aiding market growth. However, the two major threats the healthcare biotechnology sector faces in the coming years are the increasing threat of biogenerics and the difficulty in acquiring capital. Strategic partnerships will continue to be important to biotechnological drug development.

This brand new report - Global Biotech Market, 2008-2023- examines the healthcare biotech market critically, through comprehensive research and analysis. This report covers both the top ten therapy classes as well as the top ten leading pharmaceutical products in the biotech market in particular, as well as leading pipeline agents. Furthermore, applied techniques such as their in-house financial forecasting technology, SWOT analyses, R&D pipeline analysis and qualitative projections. The result is a comprehensive market-based report with detailed analysis and informed opinion.

Why you should buy this report:
In particular, our Global Biotech Market, 2008-2023 report concentrates on the following essential aspects of that market, including the competitive environment for original branded products and biogenerics:

There are significant financial benefits from a company’s having a portfolio of biotech drugs, especially in this very uncertain period, when technological and commercial change is accelerating. This realisation has caused the major pharmaceutical companies to establish themselves in the biotech market. At least half of the top ten pharmaceutical companies now have leading biotech drugs. Thinning developmental pipelines in small molecule agents can, in part, explain big pharma's embracing of the biotech market, forcing them to buy biotech firms with promising drugs in development. This report provides valuable commercial information on this exciting industry that no healthcare company should ignore.

Table of Contents

1 Executive Summary

1.1 Global Biotech Market Review: Entering a Crucial Period
1.2 Aims, Scope and Format of the Report

2 Introduction to Biotechnology

2.1 What is Biotechnology?
2.1.1 The Major Focus of Biotech Research
2.1.2 The Launch of Recombinant Insulin in 1982 was the First Commercial Biotech Drug
2.2 The Uniqueness of Biopharmaceuticals: Turning Medicine Around
2.3 Biotechnologies Used and Their Applications to Pharma
2.3.1 Bioprocessing Technology
2.3.2 Monoclonal Antibodies
2.3.3 Recombinant DNA Technology
2.3.4 Cloning
2.3.4.1 Molecular Cloning
2.3.4.2 Cellular Cloning
2.3.4.3 Animal Cloning
2.3.4.4 Protein Engineering
2.4 The Future Biopharmaceutical Market
2.4.1 Over 7000 Biotechnology Patents Granted Per Annum Since 1998
2.4.2 2005 Witnessed 54 New Biopharmaceuticals Approved by the FDA
2.5 Proteomics Constitutes the "Next Step" After Genomics
2.6 The Human Genome Project (HGP) and its Influence on Biotech
2.6.1 Overall Project Goals
2.6.2 Applications and Future Developments of the HGP
2.7 Top 10 Biotech Companies, 2007
2.8 The Top 10 Selling Biotech Drugs in 2007

3 The Leading Biotech Therapy Classes Market Forecast 2008-2013, 2018 & 2023

3.1 The Top 10 Therapy Classes – Analysis & Forecasts
3.1.1 Erythropoietins Class Currently Leads the Biotech Market – But Will it Last?
3.1.2 How Will the Oncology Class Compete with the Erythropoietins in the Biotech Market?
3.1.3 Human Insulins Class Sales Outlook from 2008 Onwards
3.1.4 Autoimmune Agents Sales Outlook from 2008 Onwards
3.1.5 The Interferons Sales Outlook from 2008 Onwards
3.1.6 Immunostim Agents Sales Outlook from 2008 Onwards
3.1.7 Immunosuppressive Agents Sales Outlook from 2008 Onwards
3.1.8 Growth Hormones Sales Outlook from 2008 Onwards
3.1.9 Blood Factors Sales Outlook from 2008 Onwards
3.1.10 Pure Vaccines Sales Outlook from 2008 Onwards
3.2 Top 10 Therapy Classes: Summary of Forecasts

4 The Global Biotech Market 2008-2013, 2018 & 2023 – Top 10 Leading Products, Analysis and Forecasts

4.1 The Global Biotech Market Showed Impressive Revenues in 2007
4.2 The Top 10 Selling Biotech Drugs of 2007 Accounted for Half of Total Biotech Drug Sales
4.3 The Top 5 Biotech Products of 2007
4.4 Enbrel Currently Leads the World Biotech Market
4.4.1 Enbrel Q1 2008 US Sales Approach Blockbuster Figures
4.4.2 Recent Concerns for Enbrel
4.4.3 Development of Enbrel
4.5 Aranesp Sales Outlook from 2008 Onwards
4.5.1 Aranesp Other International Markets Grew by 2% In 2007
4.5.2 Development of Aranesp
4.6 Remicade Sales Outlook from 2008 Onwards
4.6.1 Remicade Associated With Adverse Immunogenic Reactions
4.6.2 UK's NICE Rejects Second "go" with Arthritis Drugs
4.7 MabThera/Rituxan Sales Outlook from 2008 Onwards
4.7.1 MabThera/Rituxan (rituximab)
4.7.2 Development of MabThera/Rituxan
4.8 Neulasta Sales Outlook from 2008 Onwards
4.8.1 Neulasta (pegfilgrastim)
4.9 Procrit/Erypo Sales Outlook from 2008 Onwards
4.9.1 Procrit/Erypo Safety Concerns
4.10 Herceptin Sales Outlook from 2008 Onwards
4.10.1 Herceptin (trastuzumab) 
4.10.2 Development of Herceptin
4.11 Epogen Sales Outlook from 2008 Onwards
4.11.1 Epogen (Epoetin Alfa) - Recombinant Human Erythropoietin Product
4.12 Avastin Sales Outlook from 2008 Onwards
4.12.1 Avastin (bevacizumab)
4.12.2 Development of Avastin
4.13 Humira Sales Outlook from 2008 Onwards
4.13.1 Humira (adalimumab)
4.14 Top 10 Leading Products Summary

5 SWOT Analysis 2008-2013

5.1 SWOT Analysis of the Global Biotech Market
5.2 Market Drivers
5.3 Market Restraints
5.4 The Biotech Market is Rapidly Expanding
5.5 The Benefits of Biotechnological Products
5.6 Biotechnology is an Important and Fast-Growing Part of Healthcare R&D
5.7 Regulatory Issues
5.7.1 Biopharmaceuticals and the FDA
5.7.2 FDA Improving Upon Approval Wait
5.7.3 FDA and Other Regulatory Bodies Recommend Changes to Erythropoietin Stimulating Agents  (ESAs) Labels
5.7.4 FDA Monitors ESAs over Two Decades
5.7.5 Rising Regulatory Hurdles and High Cost of Developing Biologic Drugs Will Play to the Advantage of Big Pharma
5.8 Biotech Market Challenges
5.8.1 Biotech’s Delivery Challenge
5.8.1.1 New Delivery Technologies: A Pharmacy or Medical Benefit? 
5.8.2 Manufacturing Capacity Shortfall
5.8.2.1 Why is there a Shortfall in Manufacturing Capacity for Biopharmaceuticals?
5.8.2.2 How is the Manufacturing Capacity Shortfall Being Overcome?
5.8.3 The Costs of Biopharmaceuticals
5.8.3.1 The Top Five Biopharmaceuticals Each Cost Over $10,000 per Patient per Annum
5.8.4 The Need for Collaboration
5.8.4.1 Future Biotech Innovation and Academia
5.8.4.2 The Risky Path from Bench to Market
5.8.5 Biogeneric (Biosimilar) Threats
5.8.5.1 Strong Bioequivalence Hurdles Will Regulate the Fast Market Entry of Biogeneric Drugs
5.8.6 Dependence upon Venture Capital Investment
5.9 Biotech's Major Challenges: Biogenerics and Budgetary Restraints
5.9.1 Healthcare Costs Are Rising with Biotech Drugs Constituting a Large Part of these Costs
5.9.2 Biotech Drugs are Expensive to Develop
5.9.3 Smaller Biotech Companies Specialising in Biogenerics
5.9.4 The Next Generation of Biotech Drugs
5.10 Challenges and Issues for the Future in Healthcare Biotechnology

6 The Top 10 Leading Players in the Biotech Market

6.1 Amgen: The Reign Continues With a Prominent Share of 2007 Market
6.1.1 Amgen Background
6.1.2 Amgen - Like Other Companies - Could Benefit From Changes to Patent Laws
6.1.3 Amgen Will Continue to Compete With Big Pharma's Large Investment Trends in Biotech
6.2 The Strong Partnership Flourishes between Roche and Genentech
6.2.1 Roche in Talks to Buy Genentech Stock
6.2.2 Roche Gains Momentum in Amgen's Territory
6.3 The Continuing Success of International Biopharmaceuticals Companies is Dependent upon Important Drivers and Restraints
6.3.1 Companies Are Gradually Changing their Strategic Focus to Overcome Challenges in the Worldwide Market

7 Global Biotech Market by Region

7.1 The World Biotech Market is Dominated by the US
7.2 Japanese and European Biotech World Market Shares – How will these Develop?
7.3 The US Biotech Market Will Retain World Dominance
7.4 The European Biotech Market Will See Reduced Growth
7.4.1 Biosimilars Approval Rises In the EU Market
7.5 Biocon and Abraxis Launch Breast Cancer Drug in India

8 Venture Capital Investment in Healthcare Biotechnology

8.1 What is Venture Capital Investment?
8.2 What Do VC’s Offer?
8.3 What Do Venture Capitalists Do?
8.4 Who are Venture Capitalists?
8.4.1 Banks as Venture Capitalists
8.4.2 Business Angels as Venture Capitalists
8.4.3 Corporate or Direct Investors as Venture Capitalists
8.4.4 Government Grants and Governments as Venture Capitalists
8.4.5 Venture Capital Firms
8.4.6 Other Types of Venture Capitalist
8.5 Why Do Biotech Companies Need VC Funding?

9 Biogenerics - Overview

9.1 The Emergence of Biogenerics (Biosimilars)
9.1.1 Patent Expiry for Key Biotech Drugs
9.1.2 Names are Important

9.2 Improved Technology Has Strengthened the Case for Biogenerics
9.3 Bioequivalence Will Remain Difficult to Demonstrate
9.4 Biotech Drugs are Expensive to Develop
9.5 Regulators and Patients are Cautious over Safety   
9.6 The Next Generation of Biotech Drugs will Restrain Growth in Biogenerics 
9.7 Regulations are the Main Concern for Biogenerics
9.8 The Key Question for Biogenerics - How Innovative Do You Need to Be?

10 Biotech Pipeline

10.1 Technology Driving Biopharma Pipeline
10.2 Biotech Targeting Chronic Illness
10.3 Late-Stage Erythropoietins Pipeline
10.4 Late Stage Oncology Pipeline
10.5 Late-Stage Human Insulins Pipeline
10.6 Late-Stage Arthritis Pipeline
10.7 Late-Stage Interferons Pipeline
10.8 Late-Stage Immunostims Pipeline
10.9 Late-Stage Immunosuppressives Pipeline
10.10 Late-Stage Growth Hormones Pipeline
10.11 Late-Stage Blood Factors Pipeline
10.12 Late-Stage Vaccines Pipeline
10.13 The Future of Biotech R&D

11 Conclusions - Biotech Comes of Age

11.1 The Global Biotech Market in 2007 - Summary
11.2 The Top 5 Biotech Products of 2007 Had Impressive Sales Figures
11.2.1 Top 10 Leading Products Rank - 2007 and 2013 Comparison
11.3 Erythropoietins Class Currently Leads the Biotech Market - But Will it Last?
11.3.1 Top 10 Therapy Classes Rank - 2007 and 2013 Comparison
11.4 Can Amgen Remain at the Forefront of the Global Biotech Industry and Continue to be a Strong Competitor in the Global Pharmaceutical Market?
11.5 Biotech Drugs Often Target Niche Markets

List of Tables

  • Table 2.1 Definitions of Selected Biopharmaceuticals
  • Table 2.2 Summary of Biotechnologies
  • Table 2.3 The Top 10 Global Biotech Companies, 2007
  • Table 2.4 The Top 10 Leading Biotech Products, 2007
  • Table 3.1 Revenues ($m) for the Top Ten Therapy Classes', 2008-2013, 2018 & 2023
  • Table 3.2 Revenues ($m), 6-Year CAGR (%) and Market Share (%) for Top Ten Therapy Classes, 2007 & 2013
  • Table 3.3 Top 10 Therapy Classes Rank Comparison, 2007 and 2013
  • Table 4.1 Top 10 Leading Drugs Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Table 4.2 Top 10 Drugs 6-Year CAGR (%) and Market Share (%), 2007 & 2013
  • Table 4.3 Top 10 Products Market Share (%) Comparison 2007 & 2013
  • Table 4.4 Enbrel Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.5 Aranesp Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.6 Remicade Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.7 MabThera/Rituxan Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.8 Neulasta Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.9 Procrit/Erypo Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.10 Herceptin Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.11 Epogen Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.12 Avastin Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.13 Humira Revenues ($m) 2008-2013, 2018 & 2023
  • Table 4.14 Top 10 Products Rank Comparison, 2007 and 2013
  • Table 5.1 A SWOT Chart for the Biotech Market, 2008-2013
  • Table 6.1 Biotech Company Revenues ($m), Company Market Share (%) 2007
  • Table 7.1 Global Biotech Market Revenues ($m) Forecast 2008-2013, 2018 & 2023
  • Table 7.2 Global Market Share (%) and Revenue ($m) by Country/Region, 2007
  • Table 7.3 Global Market Share (%) by Country/Region Compared, 2007 and 2013
  • Table 7.4 Region/Country Revenue forecast ($m) 2008-2013, 2018 & 2023
  • Table 7.5 Competing Biosimilar Epoietin Launched in 2007-2008
  • Table 10.1 Late-Stage Erythropoietins Pipeline, 2008
  • Table 10.2 Late Stage Oncology Pipeline, 2008
  • Table 10.3 Late-Stage Human Insulin Pipeline, 2008
  • Table 10.4 Late-Stage Arthritis Pipeline, 2008
  • Table 10.5 Late-Stage Interferons Pipeline, 2008
  • Table 10.6 Late-Stage Immunostim Pipeline, 2008
  • Table 10.7 Late-Stage Immunosuppressive Pipeline, 2008
  • Table 10.8 Late-Stage Growth Hormone Pipeline, 2008
  • Table 10.9 Late-Stage Blood Factors Pipeline, 2008
  • Table 10.10 Late-Stage Vaccines Pipeline, 2008
  • Table 11.1 Global Biotech Market Revenues ($m) Forecast 2008-2013, 2018 & 2023
  • Table 11.2 Top 10 Products Rank Comparison, 2007 and 2013
  • Table 11.3 Top 10 Therapy Classes Rank Comparison, 2007 and 2013

List of Figures

  • Figure 2.1 Total Number of Biotechnology Patents Granted: 1992-2002
  • Figure 2.2 Number of New Biopharmaceutical FDA Approvals: 2000-2005
  • Figure 3.1 Top Ten Therapy Classes Revenue ($m) Comparison, 2007 & 2013
  • Figure 3.2 Top Ten Therapy Classes Market Share (%), 2007
  • Figure 3.3 Top Ten Therapy Classes Market Share (%), 2013
  • Figure 3.4 Erythropoietins Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 3.5 Oncology Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 3.6 Human Insulins Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 3.7 Autoimmune Agents Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 3.8 Interferons Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 3.9 Immunostim Agents Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 3.10 Immunosuppressive Agents Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 3.11 Growth Hormones Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 3.12 Blood Factors Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 3.13 Pure Vaccines Class Revenue ($m) Forecast 2008-2013, 2018 & 2023
  • Figure 4.1 Global Biotech Market Sales Breakdown ($m) 2008-2013, 2018 & 2023
  • Figure 4.2 Top 10 Drugs vs. the Rest of the Portfolio (%) Contribution of Revenues, 2007 & 2013
  • Figure 4.3 Top 10 Products Market Share (%) 2007
  • Figure 4.4 Top 10 Products Market Share (%) 2013
  • Figure 4.5 World Revenues ($m) for Enbrel 2008-2013, 2018 & 2023
  • Figure 4.6 World Revenues ($m) for Aranesp 2008-2013, 2018 & 2023
  • Figure 4.7 World Revenues ($m) for Remicade 2008-2013, 2018 & 2023
  • Figure 4.8 World Revenues ($m) for MabThera/Rituxan 2008-2013, 2018 & 2023
  • Figure 4.9 World Revenues ($m) for Neulasta 2008-2013, 2018 & 2023
  • Figure 4.10 World Revenues ($m) for Procrit/Erypo 2008-2013, 2018 & 2023
  • Figure 4.11 World Revenues ($m) for Herceptin 2008-2013, 2018 & 2023
  • Figure 4.12 World Revenues ($m) for Epogen 2008-2013, 2018 & 2023
  • Figure 4.13 World Revenues ($m) for Avastin 2008-2013, 2018 & 2023
  • Figure 4.14 World Revenues ($m) for Humira 2008-2013, 2018 & 2023
  • Figure 6.1 Company Revenues from Leading Biotech Drugs ($m), 2007
  • Figure 6.2 Top 10 Leading Biotech Companies Market Share (%) 2007
  • Figure 7.1 Global Market Share (%) by Region, 2007
  • Figure 7.2 Global Market Share (%) by Region, 2013

Other users found this report page using the following search terms: biotech biotech market 2008 global biotechnology companies top sales analysis share

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.